SCHEMBL6678658

SCHEMBL6678658

CN1CC(C(=O)OCc2ccc(F)cc2)=Cc2c1[nH]c(=O)n(Cc1ccc(C#N)cc1)c2=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
MAPK14 Q16539 1/20 0.38
GAA P10253 3/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
PGGT1B P53609 1/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALDH1A1 P00352 2/20 0.35
RECQL P46063 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP12 P39900 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6679671 0.90 MMP1 (0.40) KDM4ELMNAHTTGAAMAPT
SCHEMBL6683369 0.84 KLKB1 (0.41) KDM4ELMNAHTTRXFP1
SCHEMBL7122539 0.77 KDM4E (0.40) KDM4ELMNAHTTMAPK14GAA
SCHEMBL6683557 0.76 MMP1 (0.47) KDM4ELMNAHTTGAATSHR
SCHEMBL6664325 0.74 TRPA1 (0.46) KDM4ELMNAMAPTALDH1A1RXFP1
SCHEMBL7131191 0.72 MMP1 (0.40) KDM4ELMNAHTTGAAMAPT
SCHEMBL6678347 0.72 ALDH1A1 (0.43) KDM4ELMNAALDH1A1HSD17B10SMN1; SMN2
SCHEMBL7114939 0.69 PRKAA2 (0.39) MAPTRXFP1
SCHEMBL6695961 0.68 MMP1 (0.36) GAAMAPTALDH1A1RECQLMMP1
SCHEMBL7123023 0.67 L3MBTL1 (0.42) LMNATSHRTDP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 KDM4E 819/4885LMNA 3842/4885HTT 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.